# XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy

> **NCT04639310** · PHASE3 · TERMINATED · sponsor: **Xenon Pharmaceuticals Inc.** · enrollment: 8 (actual)

## Conditions studied

- Epilepsy
- Epilepsy in Children
- Epilepsy; Seizure
- Disease
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Epileptic Syndromes

## Interventions

- **DRUG:** XEN496
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04639310
- **Lead sponsor:** Xenon Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-29
- **Primary completion:** 2023-05-16
- **Final completion:** 2023-05-16
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Sponsor decision; Not a safety decision
- **Last updated:** 2024-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04639310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04639310, "XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04639310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*